Cellectis SA (ALCLS):製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C7958)
◆英語タイトル:Cellectis SA (ALCLS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7958
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年10月
◆ページ数:74
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:フランス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥26,750見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥53,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥80,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Cellectis SA (Cellectis) is a clinical-stage biopharmaceutical company that research, develop and commercialise rational genome engineering technologies. The company pioneers gene editing company, deploying core proprietary technologies to develop off-the-shelf immunotherapies to target and eradicate cancer cells. It develops treatment based on allogeneic T-cell for the treatment of cancer. Cellectis therapeutic pipeline products include products for hematopoietic tumors such as UCART19, UCART123, UCART33, UCART-BCMA and UCART38; and products for solid tumors including UCART5T4, UCART-EgfrVIII, s-3, s-4, s-5,s-6, and s-7. The company carries out research and development in the field of oncology and gene editing. It operates in New York and Paris. Cellectis is headquartered in Paris, France.

Cellectis SA (ALCLS) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Cellectis SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cellectis SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Cellectis SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cellectis SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Cellectis SA, Medical Devices Deals, 2012 to YTD 2018 10
Cellectis SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Cellectis SA, Pharmaceuticals & Healthcare, Deal Details 13
Partnerships 13
Wyss Institute and cellectis Enter into Collaboration 13
MolMed and Cellectis Enter into Co-Development Agreement 14
Cellectis and MabQuest Enter into Research Agreement 15
Cellectis Enters into R&D Agreement with The University of Texas MD Anderson Cancer Center 16
Weill Cornell Medical Enters into Research Agreement with Cellectis 17
ModiQuest Research Enters into Co-Development Agreement with Cellectis Bioresearch 18
Cellectis Enters Into Co-Development Agreement With Servier 19
Cellectis Enters Into Co-Development Agreement With University College London 21
Medicago Enters Into Co-Development Agreement With Cellectis 22
Licensing Agreements 23
Allogene Therapeutics Enters into Licensing Agreement with Cellectis 23
Servier Exercises Option for Licensing Agreement with Cellectis 24
Cellectis Enters into Licensing Agreement with Ohio State Innovation Foundation 25
Pfizer Enters into Licensing Agreement with Cellectis 26
Cellectis Enters into Licensing Agreement with Thermo Fisher Scientific for Gene Editing Technology 27
Cellectis Enters into Licensing Agreement with genOway 28
Cellectis Enters into Licensing Agreement with Takara Bio for RetroNectin 29
Cellectis Enters Into Licensing Agreement With Iowa State University For TAL Technology 30
Equity Offering 31
Cellectis Raises USD175 Million in Public Offering of ADS 31
Cellectis Prices Public Offering of American Depositary Shares for USD228.25 Million 33
Cellectis Raises USD16.5 Million upon Exercise of Warrants 35
Cellectis Completes Private Placement Of Shares For USD24.6 Million 36
Acquisition 37
Pfizer May Acquire Remaining 90.5% Stake in Cellectis 37
Takara Bio Acquires Cellectis, Biotech Company 38
Cellectis SA – Key Competitors 39
Cellectis SA – Key Employees 40
Cellectis SA – Locations And Subsidiaries 41
Head Office 41
Other Locations & Subsidiaries 41
Recent Developments 42
Financial Announcements 42
Aug 01, 2018: Cellectis Reports Financial Results for 2nd Quarter and First Six Months 2018 42
May 07, 2018: Cellectis Reports 1st Quarter 2018 Financial Results 46
Mar 12, 2018: Cellectis Reports 4th Quarter and Full Year 2017 Financial Results 49
Nov 13, 2017: Cellectis Reports Financial Results for Third Quarter and First Nine Months of 2017 53
Aug 02, 2017: Cellectis Reports Financial Results for 2nd Quarter and First Six Months 2017 57
May 09, 2017: Cellectis Reports 1st Quarter 2017 Financial Results 59
Mar 06, 2017: Cellectis Reports 4th Quarter and Full Year 2016 Financial Results 61
Corporate Communications 64
Aug 22, 2018: Calyxt appoints Dr. Yves J. Ribeill as Interim CEO 64
Aug 02, 2018: Cellectis Appoints Stefan Scherer M.D., Ph.D., as Senior Vice President Clinical Development and Deputy Chief Medical Officer 65
Mar 13, 2018: Dr. Mathieu Simon to Retire as Cellectis’ Chief Operating Officer; Elsy Boglioli Named as Successor 66
Dec 04, 2017: Cellectis Appoints Elsy Boglioli to Executive Vice President, Strategy and Corporate Development 67
Dec 04, 2017: Cellectis Appoints Immuno-Oncology Leader Stephane Depil to Position of Senior Vice President Research & Development and Chief Medical Officer 68
Oct 04, 2017: Mathieu Simon, M.D. Cellectis’ EVP & Chief Operating Officer, to Serve as Interim Chief Medical Officer 69
Jun 28, 2017: Cellectis Appoints Rainer Boehm, M.D. and Herve Hoppenot to Board of Directors 70
Product News 71
Nov 20, 2017: Cellectis Demonstrates Fine and Predictable Tuning of TALEN Gene Editing Targeting to Improve T-cell Adoptive Immunotherapy 71
11/01/2017: Cellectis Announces Oral Presentation of UCARTCS-1 at the 2017 ASH Annual Meeting 72
Jun 12, 2018: Cellectis Publishes Novel Methods to Improve the Clinical Use of Chimeric Antigen Receptor T-Cell Therapy in Scientific Reports 73
Appendix 74
Methodology 74
About GlobalData 74
Contact Us 74
Disclaimer 74

List of Tables
Cellectis SA, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Cellectis SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cellectis SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Cellectis SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cellectis SA, Deals By Therapy Area, 2012 to YTD 2018 9
Cellectis SA, Medical Devices Deals, 2012 to YTD 2018 10
Cellectis SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Wyss Institute and cellectis Enter into Collaboration 13
MolMed and Cellectis Enter into Co-Development Agreement 14
Cellectis and MabQuest Enter into Research Agreement 15
Cellectis Enters into R&D Agreement with The University of Texas MD Anderson Cancer Center 16
Weill Cornell Medical Enters into Research Agreement with Cellectis 17
ModiQuest Research Enters into Co-Development Agreement with Cellectis Bioresearch 18
Cellectis Enters Into Co-Development Agreement With Servier 19
Cellectis Enters Into Co-Development Agreement With University College London 21
Medicago Enters Into Co-Development Agreement With Cellectis 22
Allogene Therapeutics Enters into Licensing Agreement with Cellectis 23
Servier Exercises Option for Licensing Agreement with Cellectis 24
Cellectis Enters into Licensing Agreement with Ohio State Innovation Foundation 25
Pfizer Enters into Licensing Agreement with Cellectis 26
Cellectis Enters into Licensing Agreement with Thermo Fisher Scientific for Gene Editing Technology 27
Cellectis Enters into Licensing Agreement with genOway 28
Cellectis Enters into Licensing Agreement with Takara Bio for RetroNectin 29
Cellectis Enters Into Licensing Agreement With Iowa State University For TAL Technology 30
Cellectis Raises USD175 Million in Public Offering of ADS 31
Cellectis Prices Public Offering of American Depositary Shares for USD228.25 Million 33
Cellectis Raises USD16.5 Million upon Exercise of Warrants 35
Cellectis Completes Private Placement Of Shares For USD24.6 Million 36
Pfizer May Acquire Remaining 90.5% Stake in Cellectis 37
Takara Bio Acquires Cellectis, Biotech Company 38
Cellectis SA, Key Competitors 39
Cellectis SA, Key Employees 40
Cellectis SA, Subsidiaries 41

List of Figures
Cellectis SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Cellectis SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Cellectis SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Cellectis SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Cellectis SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cellectis SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Cellectis SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cellectis SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Cellectis SA, Medical Devices Deals, 2012 to YTD 2018 10

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Cellectis SA (ALCLS):製薬・医療:M&Aディール及び事業提携情報(Cellectis SA (ALCLS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆